What are the clinical outcomes of using cidofovir for treating verruca vulgaris and verruca plana?

Label:chem

Topic
A study provides several case reports and studies on the efficacy of cidofovir for treating recalcitrant warts.
Answer
Cidofovir has shown significant efficacy in treating verruca vulgaris and verruca plana, both topically and intralesionally. For example, a retrospective analysis of 58 patients with recalcitrant warts treated with intralesional cidofovir (15 mg/mL) reported that over 75% of patients achieved complete resolution after an average of 3.4 treatments administered monthly. Topical cidofovir has also been effective, with studies showing complete resolution in a significant number of patients, although some cases required longer treatment durations.
Return to Home Chemical List
Knowledge you may be interested in
What are the common side effects of cidofovir when used topically and intralesionally? How is cidofovir administered for cutaneous applications? What is the mechanism of action of cidofovir in treating viral infections? What were the key findings from the binding affinity and functional activity assays of the synthesized naltrindole (NTI) derivatives? What is the impact of the S=O moiety in sulfonamide-type naltrindole (NTI) derivatives on their functional activities? How do the binding affinities and functional activities of the synthesized naltrindole (NTI) derivatives compare among different substituents? What is the significance of the N-substituent in the functional activities of naltrindole (NTI) derivatives for the δ opioid receptor (DOR)? How does Zileuton influence the adaptive immune response in the spleen during MHV-3 infection? How does Zileuton impact cardiopulmonary function in MHV-3-infected mice? What are the effects of Zileuton on cytokine levels and immune cell profiles in the lungs of MHV-3-infected mice? How effective is cidofovir in treating molluscum contagiosum? What is the role of Combretastatin A4 (CA-4) in modulating oxidative stress in human peripheral blood mononuclear cells (PBMCs)? How does Combretastatin A4 (CA-4) affect the viability and metabolic activity of human PBMCs compared to cancer cell lines? What is the impact of Combretastatin A4 (CA-4) on DNA damage in human PBMCs under oxidative stress conditions? How does Combretastatin A4 (CA-4) influence the production of reactive oxygen species (ROS) in PBMCs exposed to oxidative stress? What are the potential therapeutic implications of Combretastatin A4 (CA-4) based on its selective cytotoxicity and antioxidant properties? What are the environmental risks associated with fipronil (FIP) and imidacloprid (IMID) used in pet ectoparasiticides? How do FIP and IMID affect marine organisms? What are the potential toxic effects of fipronil (FIP) and imidacloprid (IMID) on human cells? What is the impact of pentosidine on adipose tissue metabolism?